Advertisement
Singapore markets close in 17 minutes

  • Straits Times Index

    3,340.10
    -8.77 (-0.26%)
     

  • Nikkei

    38,837.46
    -85.54 (-0.22%)
     

  • Hang Seng

    18,444.11
    +41.11 (+0.22%)
     

  • FTSE 100

    8,216.50
    -46.25 (-0.56%)
     

  • Bitcoin USD

    69,061.23
    -237.05 (-0.34%)
     

  • CMC Crypto 200

    1,446.77
    -0.38 (-0.03%)
     

  • S&P 500

    5,283.40
    +5.89 (+0.11%)
     

  • Dow

    38,571.03
    -115.27 (-0.30%)
     

  • Nasdaq

    16,828.67
    +93.67 (+0.56%)
     

  • Gold

    2,355.00
    -14.30 (-0.60%)
     

  • Crude Oil

    73.15
    -1.07 (-1.44%)
     

  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     

  • FTSE Bursa Malaysia

    1,615.69
    +19.01 (+1.19%)
     

  • Jakarta Composite Index

    7,113.91
    +77.71 (+1.10%)
     

  • PSE Index

    6,386.42
    -84.32 (-1.30%)
     

MeiraGTx Holdings First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

MeiraGTx Holdings (NASDAQ:MGTX) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$697.0k (down 79% from 1Q 2023).

  • Net loss: US$20.4m (loss narrowed by 33% from 1Q 2023).

  • US$0.32 loss per share (improved from US$0.62 loss in 1Q 2023).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

MeiraGTx Holdings Earnings Insights

Looking ahead, revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 2.0% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with MeiraGTx Holdings (at least 1 which is a bit unpleasant), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.